The TNBC treatment landscape is transforming through biomarker-driven therapies and immunotherapy innovations. Key players including Merck, Gilead, and AstraZeneca are developing novel antibody-drug conjugates, immune checkpoint inhibitors, and targeted therapies that improve survival outcomes. Advancements in molecular profiling and combination approaches are enabling more personalized treatment strategies for this aggressive breast cancer subtype. Access Market Report: https://shorturl.at/ruuiQ